Eflornithine Hydrochloride

IFINWIL®: now approved in Switzerland1 Nine out of 10 cases of neuroblastoma occur in children under the age of five2 The average survival rate of children with HRNB is only 50%2 UXBRIDGE, England, July 8, 2025 /PRNewswire/ -- Norgine, a leading European specialty pharmaceutical company, is pleased to announce that Swissmedic has approved the registration of IFINWIL® (eflornithine) as monotherapy for the treatment of paediatric patients from one year with high-risk neuroblastoma (HRNB)1. "This milestone marks a further regulatory approval of IFINWIL® for high-risk neuroblastoma, following approvals in the US, Israel and Australia," said Jörg Plessl, VP and Head of Global Regulatory Affairs at Norgine. "We deeply appreciate Swissmedic and the other Project Orbis partners for their keen awareness of the distinct challenges associated with paediatric oncology. Their agility in utilizing adaptive regulatory pathways is crucial because the stakes are incredibly high when it comes to children's lives. In these situations, speed and flexibility are not just advantageous, they can make all the difference." "By collaborating with international regulatory partners through Project Orbis, we are advancing our strategy to broaden access to innovative therapies for paediatric patients in Europe and ANZ." said Dr David Gillen, Chief Medical Officer at Norgine. "At Norgine, we're proud to take on some of the most complex disease areas, driven by our mission to deliver meaningful treatments where they're needed most." HRNB is a rare but aggressive form of cancer, predominantly affecting children and most commonly presenting in the first 5 years of life.2 Globally, neuroblastoma affects approximately 10.2 children per million annually under age 15, with around 50% of cases classified as high-risk at diagnosis.3,4 Neuroblastoma originates in the body's nerve cells (neuroblasts) and typically presents as a primary tumour in the adrenal glands.5 It is considered an aggressive tumour because it often spreads to other parts of the body (metastasises). In most cases, it has spread by the time it is diagnosed.5 Despite intensive multimodal therapy, the 5-year survival rate for HRNB remains below 50%, compared to up over 95% for infants with low-risk disease.2,6 Neuroblastoma accounts for approximately 15% of all paediatric cancer-related deaths, underscoring the urgent need for more effective treatment options.7 About IFINWIL® IFINWIL® has been investigated for use as a post maintenance treatment for high-risk neuroblastoma (HRNB) in paediatric patients with no active disease (NAD) / no evidence of disease (NED) after first line multiagent, multimodality therapy.8 IFINWIL® is a therapy that blocks an enzyme called ornithine decarboxylase (ODC) responsible for producing polyamines, which are important to tumour growth and development.9 High-Risk Neuroblastoma (HRNB) Treatment Background Children diagnosed with HRNB undergo an intense treatment regimen that still leaves them vulnerable to relapse and death.10 Although there have been some improvements in survival, the prognosis for children with high risk neuroblastoma is still poor with around 80% of high risk relapses occuring within 2 years from diagnosis, and long-term survival remains low, with only about 15% surviving more than 5 years post-relapse.11,12,13 Avoiding relapse is key to long-term survival, and until now, there have been no approved therapies for the post maintenance treatment period in major markets outside of the United States.14 About Project Orbis Project Orbis is an initiative (since May 2019) of the US FDA Oncology Center of Excellence (OCE) and provides a framework for concurrent submission and collaborative review of innovative oncology products among international regulatory authorities. It was created with the overarching goal to speed worldwide patient access to innovative cancer therapies. Project Orbis is coordinated by the FDA, and its partners include United Kingdom Medicines and Healthcare Products regulatory Agency (UK MHRA), Australia Therapeutic Goods Administration (TGA), Canada (Health Canada), Singapore (Health Sciences Authority (HSA), Switzerland (Swissmedic), Brazil (Agência Nacional de Vigilância Sanitária (ANVISA), Israel (Ministry of Health). In April 2024, Norgine submitted an application for approval of eflornithine in high-risk neuroblastoma (HRNB), via Project Orbis in Australia, Switzerland and the United Kingdom. In April 2025, the Australian Therapeutic Goods Administration (TGA) approved the registration of IFINWIL® for the treatment of adults and paediatric patients with HRNB, who have responded to prior multiagent, multimodality therapy. These regulatory milestones support Norgine's efforts to deliver patient access to IFINWIL® and bring a further treatment option in the field of paediatric oncology. About Norgine Norgine is a leading European specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. Our commitment to transforming people's lives drives everything we do, and our European experience, fully integrated infrastructure and exceptional partnership approach enable us to quickly apply creative solutions to bring life-changing medicines to patients that they may not otherwise be able to access. Norgine is proud to have helped more than 25 million patients around the world in 2022 and generated €530 million in net product sales, a growth of nearly 5% over 2021. Norgine has a direct presence in 16 European countries, as well as Australia and New Zealand. We also have a strong global network of partnerships in non-Norgine markets. We are a flexible and fully integrated pharmaceutical business, with manufacturing (Hengoed, Wales and Dreux, France), third party supply networks and significant product development capabilities, in addition to our sales and marketing infrastructure. This enables us to acquire, develop and commercialise specialist and innovative products that make a real difference to the lives of patients around the world. NORGINE and the sail logo are trademarks of the Norgine group of companies. References 1. Swissmedic Journal. Swissmedic Journal Accessed July 2025 2. . Accessed June 2025. 3. Neuroblastoma Treatment (PDQ®) - NCI 4. Steven G. DuBois et al. High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes. Am Soc Clin Oncol Educ Book 42, 768-780(2022). 5. . Accessed June 2025 6. Herd F, Basta NO, McNally RJQ, Tweddle DA. A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma. Eur J Cancer. 2019 Apr;111:50-58. 7. Accessed June 2025 8. Clinical Trial NCT02395666; Preventative trial of difluoromethylornithine (DFMO) in high risk patients with neuroblastoma that is in remission. Available from: Study Details | Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission | ClinicalTrials.gov. 9. Meyskens FL Jr, Gerner EW. Development of Difluoromethylornithine (DFMO) as a Chemoprevention Agent. Clin Cancer Res. 1999 May;5(5):945-51 10. Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, et al. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016;115:1048-57. 11. Desai A, et al. Outcomes Following GD2-Directed Post consolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. J Clin Oncol. 2022 Jul; JCO2102478. 12. Basta NO, Halliday GC, Makin G, et al. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016;115(9):1048-1057. doi:10.1038/bjc.2016.302. 13. London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. Cancer. 2017;123:4914-23. 14. FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma | FDA, Accessed 04.07.25 Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

保障“十四五”顺利收官高位谋划“十五五”发展规划SPH各板块经营工作稳步推进中战略协同、产业能级、品牌效益持续提升上实集团、上海医药领导一行调研上药好护士、辽宁医贸6月11日-12日，上实集团副总裁、上海医药监事长徐有利，上实集团副总裁、上海医药集团党委书记、董事长杨秋华，上海医药执行董事、总裁沈波，上海医药集团纪委书记余卫东等一行调研上药好护士、辽宁医贸，就企业业务发展及“十五五”规划情况进行专题研讨交流。基于多年的精耕细作，上药在东北已形成创新研发、中药生产、医药商业的全产业链发展格局。此次调研旨在为企业精准把脉，为全面完成年度经营指标任务注入动力，更对当前业务进行深刻剖析，前瞻性、科学性谋划“十五五”规划，为企业长远发展把方向、拓新局。上药控股携手博安生物达成战略合作6月11日，上药控股与绿叶生命科学集团旗下山东博安生物技术股份有限公司正式签署战略合作协议，获得博安生物自主研发的GLP-1受体激动剂类降糖药度拉糖肽注射液（BA5101）在中国大陆地区的独家全渠道终端推广及全国总经销权。此次合作标志着上药控股在以自身卓越CSO能力助力创新药企优质产品实现商业化的战略征途上迈出了坚实的一步。上药控股全力保障赛生药业依氟鸟氨酸 (Eflornithine) 于上海先行先试近日，经国家药监局综合司会同国家卫生健康委研究，为保证患者救治需要，批复同意上海交通大学医学院附属上海儿童医学中心和上海市儿童医院临时进口依氟鸟氨酸（Eflornithine），用于特定患者的治疗。这标志着在国家部委支持下，上海为特定患儿打通国际创新药物临床急需临时进口通道取得关键进展。上药控股作为该临床急需药品在上海临时进口落地的指定保障方，充分发挥全球供应链优势，全力保障上海“临时进口、国内未注册”药品先行先试顺利落地。上药科园贸易与乐普生物达成战略合作6月16日， 乐普生物科技股份有限公司与科园信海（北京）医疗用品贸易有限公司在京举行了战略合作签约。此次合作表标志着双方在药品可达性、精准医疗服务和健康生态共建领域迈出关键一步，为患者提供更为高效、专业的全链条健康解决方案。同时，双方将就品牌管理、市场拓展和多元渠道覆盖等方面建立长期的、更为深入的合作，实现优势互补，合作共赢。信谊实力绽放CHINAGUT 2025中国肠道大会6月6日至8日, CHINAGUT 2025中国肠道大会在宁波成功举办，信谊作为微生态领域的深耕者重磅亮相此次大会，大会特设“菌衡纪元·培菲康30周年星耀盛典”启动仪式，与会者共同见证这一高光时刻。信谊在本届肠道大会上倾力打造了以“微生态+大健康”为核心主题的专业展区。从经典微生态制剂培菲康（双歧杆菌三联活菌）领衔的药品线，到以益生菌、益生元为核心成分的多元化健康食品，每一款产品的研发理念、核心成分与作用机制均深度植根于微生态科学，旨在让“中国菌”赋能全球健康！在大会颁奖典礼上，信谊还荣膺了“2023-2025医药与医疗服务实力企业”。立足上市三十周年的新起点，培菲康将继续携手学界与产业同仁，聚焦微生态领域的科学探索与技术创新，共同描绘一个由微生态科学守护的健康未来。上药厦中非遗产品亮相第九届成都国际非物质文化遗产节近日，以“增进交流互鉴、激发传承活力、共享美好生活”为主题的第九届中国成都国际非物质文化遗产节在成都国际非物质文化遗产博览园成功举办。在这场汇聚五湖四海非遗传承人、专家学者和非遗代表性项目的非遗盛宴上，厦门中药厂有限公司携八宝丹传统制作技艺及六味地黄丸传统制作技艺惊艳亮相“创意生活”国际非遗品牌IP授权展区，通过互动体验、动态讲解等多样形式，向海内外游客展现中国医药文化的独特魅力，成为现场焦点之一。上药雷允上、上药神象、上药华宇参加2025年徐汇区“文化和自然遗产日”主题活动上下滑动查看6月14日，2025年徐汇区“文化和自然遗产日”主题活动在上海植物园举办。活动以“文化遗产凝聚城区魅力，中医智慧滋养都市生活”为主题，9个多元场景展区游园会联动，为市民奉上了一场中医药文化与非遗交相辉映的盛宴。作为“国家级非物质文化遗产代表性项目——六神丸制作技艺”的守护者，上药雷允上携“国药精粹”惊艳亮相，以“非遗+健康”的形式，让市民近距离感受传统中医药文化的独特魅力，见证“雷氏”老字号品牌在传承中焕发的青春风采。上药神象全新IP形象“神小象”与多名外国留学生组成CP参与游园活动，现场直播亲身体验中医的博大精深与非遗的无限魅力；同时展台吸引了众多外国留学生驻足。他们不仅专注聆听着中医理念如何融入日常起居饮食，更兴致勃勃地体验产品，通过这种沉浸式体验，千年中医文化正以看得见、摸得着、尝得到的方式，向世界展示着东方养生之道的独特魅力。上药华宇带来的古法中药香囊制作体验成为手作区的焦点，驱蚊防虫、安神助眠、芳香化湿、预防感冒等功效的中药香囊吸引了众多市民朋友的目光，大家热情高涨，纷纷上手体验抓药、捣药、包药等香囊手作过程；现场还展示了铁碾船、铜舂、碾钵等古法器具以及由华宇青年制作的经典明方中药标本贴画，同时带来了贵细中药材真伪鉴别的科普，活动现场气氛热烈。